SCHEDULE: Goldman Sachs Discloses Karyopharm Therapeutics Stake

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 5.1% of Karyopharm Therapeutics Inc. common stock as of March 31, 2026.

Summary

• This filing is a Schedule 13G, indicating that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC beneficially own 991,363.52 shares of Karyopharm Therapeutics Inc. common stock.
• This ownership represents 5.1% of the class of securities.
• The filing date is April 3, 2026, and the event date requiring the filing was March 31, 2026.
• The Goldman Sachs Group, Inc. is organized in Delaware, and Goldman Sachs & Co. LLC is organized in New York.
• Goldman Sachs & Co. LLC is identified as a broker-dealer, options trader, and investment advisor.
• The filing confirms that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports ownership by a financial institution and does not contain operational or financial performance data for the company itself.

Positives

• Goldman Sachs, a major financial institution, has a significant stake (5.1%) in Karyopharm Therapeutics, which could be interpreted as a positive signal of institutional confidence.
• The filing indicates that the shares are held in the ordinary course of business, suggesting a standard investment rather than a hostile or activist intent.

Negatives

• The filing does not contain any negative financial or operational information about Karyopharm Therapeutics; it solely reports ownership by Goldman Sachs.

Risks

• As a Schedule 13G filing, it primarily concerns ownership and does not detail specific risks related to Karyopharm Therapeutics' business operations or market position.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Karyopharm Therapeutics' future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings from major financial institutions like Goldman Sachs often signal significant institutional interest in a company's stock, potentially influencing market perception and investor sentiment.

Stakeholder Impact

• Shareholders may view the significant stake held by Goldman Sachs as a positive indicator of institutional interest, potentially supporting stock price stability or growth.
• The filing does not directly impact employees, customers, suppliers, or creditors of Karyopharm Therapeutics.

Next Steps

• The Powers of Attorney granted to individuals for executing filings are valid until July 16, 2026, unless revoked earlier.

Key Dates

Keywords

Karyopharm Therapeutics, Schedule 13G, Goldman Sachs, beneficial ownership, common stock, SEC filing, institutional investor